Kenneth C. Frazier - 04 Feb 2026 Form 3 Insider Report for Eikon Therapeutics, Inc. (EIKN)

Role
Director
Signature
/s/ Benjamin Thorner, Attorney-in-Fact
Issuer symbol
EIKN
Transactions as of
04 Feb 2026
Net transactions value
$0
Form type
3
Filing time
04 Feb 2026, 21:21:22 UTC
Previous filing
08 Nov 2022
Next filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
FRAZIER KENNETH C Director C/O EIKON THERAPEUTICS, INC., 230 HARRIET TUBMAN WAY, MILLBRAE /s/ Benjamin Thorner, Attorney-in-Fact 04 Feb 2026 0001181175

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EIKN Stock Option (Right to Buy) 04 Feb 2026 Common Stock 67,043 $9.85 Direct F1
holding EIKN Stock Option (Right to Buy) 04 Feb 2026 Common Stock 16,760 $9.85 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option will vest in equal monthly installments for four years after the vesting starting date, subject to the Reporting Person's continued service through each date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney